We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 60.50 | 60.00 | 61.00 | 60.50 | 60.50 | 60.50 | 14,770 | 07:44:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.77 | 8.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/3/2020 23:36 | Bleepa is the only communications platform that allows clinicians to share & discuss patient cases using clinical-grade imaging on their personal devices. We provide #NHS staff with the tools they need to work safely&remotely. We are here to support during #coronavirusOutbreak | ged5 | |
17/3/2020 23:34 | Thanks @rijan44 . We are offering @BleepaMe for free to any #NHS Trust that need a remote image sharing and communication solution to protect staff during the coronavirus outbreak. We are answering the call and looking to help That's the way to go Tom. Good lad! Hope they take you up on this. | ged5 | |
16/3/2020 16:26 | Predicting Outcome In Childhood Diffuse Midline Gliomas Using Magnetic Resonance Imaging Based Texture Analysis METHODS: Retrospective study of patients diagnosed with DMG, based on radiological features, treated at our institution 2007-2017. MRIs were acquired at diagnosis and 6 weeks after radiotherapy (54Gy in 30 fractions). MRTA was performed using commercial available TexRAD research software on T2W sequence and Apparent Diffusion Coefficient (ADC) maps encapsulating tumour in the largest single axial plane. MRTA comprised filtration-histogram technique using statistical and histogram metrics for quantification of texture. Kaplan-Meier survival analysis determined association of MRI texture parameters with OS. | lr2 | |
16/3/2020 16:22 | Yep, that's what it looked like to me. | lr2 | |
16/3/2020 15:56 | Looking at the tiny price difference now, maybe it was just someone moving a holding between different wrappers | davydoo | |
16/3/2020 10:19 | wow. 2 stonking buys at 0.60 earlier this morning | davydoo | |
15/3/2020 18:19 | Best to restrict your travelling to quiet times to avoid contact with other people as much as possible. I've had flu twice. It's completely debilitating. All you can do is keep the temperature down, sleep as much as possible and drink water. Too many people confuse a bad virus with flu. Now is the time to get Bleepa out to the front line in as many places as possible. If it's liked then the sales will come It would be quite ironic if TexRAD became the main product for Feedback! Take care. | ged5 | |
15/3/2020 16:04 | Just popped in from planting some spuds and saw your post. Thanks LR2. "An international collaboration has recently begun working on a standardization for extraction of image biomarkers in radiomics" Perhaps TexRAD might come back to the fore. Coronavirus attacks the lungs TexRAD lung may have a part to play. Surely Bleepa could be useful in this crisis. Is your sister being isolated? Is she considered one of the vulnerable ones? | ged5 | |
15/3/2020 15:02 | Firstly, only a few clinical software packages are currently available (Dosisoft, OncoRadiomics, TexRad), although a larger number will undoubtedly emerge in the future. Interestingly, some research tools are free of charge (IBEX, CGITA, CERR, QMaZda, LifeX, Pyradiomics, RaCaT) allowing more easily the spreading of radiomics among medical community. | lr2 | |
13/3/2020 17:23 | Expect it to be cancelled or postponed davy. | ducatiman | |
13/3/2020 14:51 | Thanks. That#s just around the corner from me, so I will go and err feedback | davydoo | |
13/3/2020 14:13 | Let’s hope they have something to say | ducatiman | |
13/3/2020 13:51 | Feedback presenting in London on 26th March. (Remove hyphen) | ged5 | |
13/3/2020 09:48 | I bought 500k at .46 last night 500k at .45 this morning Hopefully this is the bottom here. I see a resignation in my clients to just accept this now. No ones selling With some buying interest | davydoo | |
12/3/2020 16:57 | If Directors have money to spend theyll be earmarking it for a future fund raise, they'll need that capital, buying shares off a disgruntled holder will do nothing | davydoo | |
12/3/2020 16:50 | Don't think director buying will make any difference here for now. Instead of spending time om you tube they should be updating the market with an RNS on how the trial was progressing, what other collaborations have being going on in the background etc. | digger2779 | |
12/3/2020 16:24 | Wonder if any directors think this is cheap enough for them to buy any shares? I don't own any of these now but this is a truly shocking SP | dplewis1 | |
12/3/2020 14:18 | Companies that need to raise in this environment are the ones in the most trouble. Need a contract now. | czc9 | |
12/3/2020 14:05 | the issue now becomes not just will they deliver but can they raise again before they do | davydoo | |
12/3/2020 12:35 | And flush! | ducatiman | |
10/3/2020 12:50 | CE Mark can’t be far off. | ducatiman | |
10/3/2020 09:30 | LOL FDBK need good sales people. | ged5 | |
10/3/2020 09:23 | Buy now! special offer! 50% off the recent placing price! | davydoo | |
09/3/2020 20:15 | If further funds are required to pay running expenses and orders are coming in the near future, then why dilute the share? Surely an overdraft facility would do the job | sonie01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions